top of page
Search

Vyepti migraine treatment at Cardinal Headache Center

Living with chronic migraines can be a debilitating experience. These severe headaches not only interfere with our daily tasks but also diminish our quality of life. But as science advances, so does the hope for more effective migraine treatments. One of the recent breakthroughs in this realm is Vyepti. In this blog post, we're going to delve into what Vyepti is, how it functions, and who might benefit from it. And if you're wondering where you can access this treatment, look no further than Cardinal Headache Center.


 

What is Vyepti? Vyepti is the brand name for eptinezumab, an FDA-approved intravenous (IV) treatment for migraine prevention in adults. As a monoclonal antibody, Vyepti specifically targets the calcitonin gene-related peptide (CGRP), a protein believed to play a pivotal role in causing migraines.


Vyepti migraine treatment at Cardinal Headache Center

How Does Vyepti Work? Our body produces CGRP, a protein that can dilate blood vessels in the brain. Elevated levels of CGRP are associated with migraines. Vyepti works by binding to CGRP and preventing its interaction with its receptor. By doing this, Vyepti helps reduce the frequency, duration, and severity of migraines.

Who Might Be Eligible for Vyepti? While Vyepti promises to be a game-changer, it's not for everyone. It is specifically designed for adult migraineurs who:

  • Have frequent migraine attacks, usually 4 or more per month.

  • Have tried other preventive medications but didn’t find them effective or had adverse side effects.

  • Don't have a history of allergies or severe reactions to CGRP or CGRP receptor antagonist medicines.

Why Choose Cardinal Headache Center for Vyepti Treatment? We pride ourselves on offering the latest and most effective treatments for headaches and migraines. Schedule your appointment with us today and to see if Vyepti migraine treatment at Cardinal Headache Center is the right choice for you.


Cardinal Headache Center logo


10 views0 comments

Comments


bottom of page